The Time for Low-Dose Computed Tomography Screening Is Now: A Medical Oncologist Perspective
November 15th 2014The NLST is a landmark trial demonstrating that implementation of low-dose CT screening lowers lung cancer–related mortality. We must put the study results and cost-effectiveness analyses in the context of the staggering statistics: up to 65% of lung cancer patients present with advanced-stage disease where treatments are often costly, toxic, and only palliative in nature.
CT Lung Cancer Screening: Public Healthcare Policy and Guidelines Collide
November 15th 2014The development of CT lung cancer screening, the publication of results from the NLST in 2011, and the grade-B recommendation for CT lung cancer screening in high-risk smokers by the USPSTF raise a number of interesting national health policy issues.
National Lung Screening Trial Limitations and Public Health Policy
November 15th 2014NLST data clearly demonstrate that lung cancer screening is effective and safe and reduces lung cancer-specific mortality by at least 20%. There is no possible reason for CMS to further delay or restrict lung cancer screening for those at high risk.
The Surgeon General vs the Marlboro Man: Who Really Won?
November 7th 2014The images in this slide set are from an exhibition curated by Alan Blum, MD, at the University of Alabama Gorgas Library (November to December 2013) to commemorate the 50th anniversary of the Surgeon General’s Report on Smoking and Health, released on January 11, 1964 by Dr. Luther Terry.
ACR Appropriateness Criteria® Rectal Cancer: Metastatic Disease at Presentation
The management of rectal cancer in patients with metastatic disease at presentation is highly variable. Although chemoradiation is standard for patients with stage II/III rectal cancer, its role in the metastatic setting is controversial.